Cassava Sciences (SAVA)’ trial for simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer’s disease, named “REFOCUS-ALZ,” has been “terminated” in a “sponsor decision,” according to a posting to ClinicalTrials.gov that shows a last update date of February 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences to reduce workforce by 33%
- Cassava Sciences call buyer realizes 60% same-day gains
- Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP
- Largest borrow rate increases among liquid names